May 22, 2018   SOURCE: PR NewsWire

Accuray CyberKnife® Customer Achieves Top Score in Multiple Brain Metastases TROG 2018 Treatment Plan Study

Accuray CyberKnife® Customer Achieves Top Score in Multiple Brain Metastases TROG 2018 Treatment Plan Study

- Results Demonstrate Exceptional Treatment Plan Quality Achievable with Accuray Treatment Planning Software (TPS)

- Renowned Clinical Trials Group TROG Cancer Research and ProKnow Partnered to Host Study

SUNNYVALE, Calif., May 22, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Daniela Schmitt, PhD, a medical physicist at Heidelberg University Hospital, took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery (SRS) Brain, with a plan she created using the Accuray Precision(®) Treatment Planning System. Dr. Schmitt developed a plan for delivery on the CyberKnife(®) M6(TM) System, a device designed from the ground up to deliver SRS treatments with precision and accuracy, and without an invasive frame. The study, hosted by TROG Cancer Research and ProKnow, received 160 entries from clinicians around the world. Of these submissions, only 10 percent were plans produced by the proprietary Accuray Precision System or the MultiPlan(®) TPS for the CyberKnife platform, while the remaining 90 percent were created using treatment planning software for other delivery systems, making a win by a physicist using Accuray TPS even more impressive.

The goal of the study was to quantify the capabilities of different planners and delivery modalities to create high quality treatment plans for a challenging SRS case with five small brain metastases. The plans were scored based on target coverage and organ-at-risk (OAR) sparing, defined by specific metrics. Evaluation of the plans was objective and transparent with real-time scoring and analysis. For more information on the plan study, register at ProKnow by visiting https://proknowsystems.com/planning/studies/5a0f6aa074403fbcc665424c1b13eaf2/population.

"It was a great experience to compete with all available systems for SRS treatments," said Daniela Schmitt, PhD, department of radiation oncology, Heidelberg University Hospital. "We often use the CyberKnife to treat patients with multiple brain metastases and now have confirmation of our good clinical practice. Treatment planning studies like this can help the whole community to find the best solution with their systems and to achieve the best daily clinical treatment plans based on the lessons learned."

The Accuray Precision System is a powerful, full-featured treatment planning system, enabling clinicians to efficiently generate high quality radiation therapy treatment plans for all SRS and stereotactic body radiation therapy (SBRT) cases delivered by the CyberKnife System.

    --  Treatment planning is faster and easier to perform, without sacrificing
        the precision and accuracy in radiation dose delivery that clinicians
        have come to expect with the CyberKnife System
    --  Simplified workflows, automated contouring and plan automation tools
        support highly efficient plan generation for even the most complex
        clinical cases
    --  Defining the target and OAR correctly can be achieved easily due to
        multimodality images and powerful and automated contouring tools

"We congratulate Dr. Schmitt on the creation of an outstanding plan. Her achievement demonstrates what is possible when clinical skills are partnered with innovative technology," said Lionel Hadjadjeba, M.D., Senior Vice President, and Chief Commercial Officer at Accuray. "The Accuray Precision System represents an important step forward in our treatment planning capabilities. When combined with the CyberKnife M6 System the resulting precision, versatility and efficiency make these technologies an ideal choice for the management of multiple brain metastases, an indication increasingly being treated with SRS."

The CyberKnife(®) System is routinely used to treat conditions in the brain, including, but not limited to, benign and malignant primary tumors, brain metastases, trigeminal neuralgia, acoustic neuromas and arteriovenous malformations (AVMs). The system enables the clinical team to achieve maximal sparing of brain tissues involved in important functions such as hearing and vision.

About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter and YouTube.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, and patient experiences and outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, the company's ability to manage its growth, and ability to maintain or increase its gross margins on product sales and services and such other risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2017, the company's quarterly report on Form 10-Q, filed with the SEC on May 2, 2018 and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.


    Media Contacts
    --------------

    Beth Kaplan                        Jayme Maniatis

    Public Relations Director, Accuray MSLGROUP

    +1 (408) 789-4426                                       +1 (781) 684-0770

    bkaplan@accuray.com                accuray@mslgroup.com

View original content with multimedia:http://www.prnewswire.com/news-releases/accuray-cyberknife-customer-achieves-top-score-in-multiple-brain-metastases-trog-2018-treatment-plan-study-300652276.html

SOURCE Accuray Incorporated